Pages

▼
Wednesday, April 29, 2015

HBsAg Rules at International Liver Congress

›
Now that the HBV world has gathered extensive clinical experience with interferons and polymerase inhibitors (NUCs) and with the resolve...
10 comments:
Monday, April 27, 2015

Regulus Therapeutics RG-101 Continues to Have Potential in HCV Treatment Landscape

›
Having attended the International Liver Congress last week in Vienna, Austria, it has become clear to me that HCV is not going away soon...
10 comments:
Thursday, April 23, 2015

Absolute HBsAg Levels, Not Percent Decline May Be Goal of HBV RNAi

›
I just walked into an early morning session at the International Liver Congress in Vienna and may have learned the most important nugget o...
7 comments:
Wednesday, April 22, 2015

First RNAi Therapeutic Nearing Finish Line

›
ALN-TTR02 for the treatment of TTR amyloidosis is the most advanced RNAi Therapeutic in clinical development and has been carrying the tor...
7 comments:
Sunday, April 19, 2015

Checkpoints Drugs Promise to Unlock RNA Therapeutics Cancer Potential

›
If you are involved in cancer drug development, you are probably thinking of ways to exploit checkpoint inhibitors for your purposes.  Che...
1 comment:
Wednesday, April 8, 2015

AstraZeneca Selects MicroRNA Development Candidate, Blazes Innovative Trail

›
When it is screaming into your face that your business model has failed you and the young competition is running circles around you, only ...
4 comments:
Tuesday, April 7, 2015

Time is running out for Benitec

›
Benitec announced today that almost 1 ½ years after filing an IND for its DNA-directed RNAi HCV candidate, it has now obtained liver biop...
30 comments: